TNFRSF17 and plasma cell myeloma: An ongoing phase 1 trial (NCT04093596) for R/R myeloma treated with ALLO-715, an allogeneic anti-BCMA CAR T cell with a disrupted TCR and CD52 gene to reduce risk of GVHD, was presented at the ASH 2021 national meeting.